Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Nonapeptide-1

Melanostatine-5, White 05

Quick Stats
Studies 4
Trials 100
Unknown NA INTERVENTIONAL NCT04642586

Detection of Subclinical Cerebral Suffering Related to Hypertension Using Multimodal MRI

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Investigators propose here to study the brain consequences of hypertension in patients without cognitive complaints and neurological signs. The evaluation of brain suffering requires considering various possible brain damage. The team developed a multimodal MRI approach capable of detecting and quantifying numerous indices (e.g. morphometric, microstructural) to evaluate possible brain suffering. This project aims to identify individually signs of cerebral suffering in hypertensive patients compared to a population of normotensive volunteers, using advanced multiparametric MRI methods.

Detailed Description

Hypertension is a risk factor for many brain pathologies, such as ischemic and hemorrhagic neurodegenerative diseases or stroke. The literature seems to agree on the relationship between hypertension and brain damage, and on the benefit of the management of hypertension to prevent certain neurological pathologies. However, to our knowledge, no single study has shown signs of subclinical brain damage in patients with hypertension. At present, no brain MRI is recommended in these patients. In the present study, hypertensive and normotensive patients will undergo a neurological exam, a neuropsychological exam, a biological exam and a MRI exam to individually identify signs of cerebral suffering.

Interventions

Name: multimodal magnetic resonance imaging
Type: DIAGNOSTIC_TEST
Description: Brain MRI exam (without contrast injection)
Name: blood test
Type: DIAGNOSTIC_TEST
Description: Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
Name: neuropsychological assessment
Type: DIAGNOSTIC_TEST
Description: neuropsychological assessment

Primary Outcomes

Measure: Presence of a cerebral zone with a z-score > 1.96
TimeFrame: through study completion, an average of 1 year
Description: the proportion of hypertensive patients who have at least one sign of cerebral suffering compared to the control group will be determined. For each MRI parameter, after coregistration, z score maps will be calculated for each hypertensive patient (individual vs normotensive group). The notion of cerebral suffering sign will be defined by the presence of a cerebral zone with a z-score greater than 1.96 (corresponding to a threshold of significance p \<.05).

Trial Information

NCT ID

NCT04642586

Status

Unknown

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

University Hospital, Toulouse

Last Updated

December 15, 2025